ZipCode Bio

Executive Summary

ZipCode Bio is a San Francisco-based biotechnology company founded in 2019, focused on developing genetic testing and diagnostic solutions for personalized medicine. The company leverages artificial intelligence and proprietary extra-hepatic delivery technologies to advance its platform. Its core capabilities include AI-driven genomic analysis and targeted delivery of genetic therapies beyond the liver, enabling a broader range of therapeutic applications. ZipCode Bio's public strategy emphasizes partnering with biopharma companies to further develop and commercialize these technologies, positioning itself as a platform enabler rather than a standalone drug developer. Given its early stage and limited public information, ZipCode Bio's progress is not widely tracked. However, the combination of AI and extra-hepatic delivery addresses significant unmet needs in precision medicine, such as non-viral delivery to tissues like muscle, lung, and CNS. The company's success hinges on attracting strategic partnerships and securing funding to advance its pipeline. With a concentrated focus on platform development, ZipCode Bio is well-positioned to capitalize on the growing demand for targeted genetic medicines, though execution and differentiation remain key risks.

Upcoming Catalysts (preview)

• H2 2026Announcement of strategic partnership with a biopharma company60% success
• Q4 2026Series A funding round closing50% success
• Q1 2027Proof-of-concept data for extra-hepatic delivery platform in animal models40% success